Clik here to view.
Isotechnika’s NICAMs demonstrate anti-viral activity
Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the...
View ArticleClik here to view.
Isotechnika highlights upcoming milestones in Q3 report
Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement...
View ArticleClik here to view.
Zalicus awaiting data on potential new pain medication
Zalicus (NASADQ:ZLCS) will have data in the second half of this year that will provide important insights into the potential of its lead drug candidate, Z160, to be a breakthrough new class of...
View ArticleClik here to view.
Xenon still committed to TV-45070 for neuropathic pain
Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for...
View Article
